<table class="naaccr-summary-table naaccr-borders">
  <tr>
    <th class="naaccr-summary-header naaccr-borders">Item #</th>
    <th class="naaccr-summary-header naaccr-borders">Length</th>
    <th class="naaccr-summary-header naaccr-borders">Source of Standard</th>
    <th class="naaccr-summary-header naaccr-borders">Year Implemented</th>
    <th class="naaccr-summary-header naaccr-borders">Version Implemented</th>
    <th class="naaccr-summary-header naaccr-borders">Year Retired</th>
    <th class="naaccr-summary-header naaccr-borders">Version Retired</th>
  </tr>
  <tr>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">3816</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">2</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">NAACCR</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">2018</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">18</td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
    <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
  </tr>
</table>

<br/><strong>NAACCR XML</strong>: Tumor.brainMolecularMarkers<br/><br/>

<div class='content chap10-para-head'><strong>Description</strong></div>
<div class='content chap10-para'>
<p>Multiple brain molecular markers have become standard pathology components necessary for diagnosis. This data item captures clinically important brain cancer subtypes identified by molecular markers that are not distinguishable by ICD-O-3 codes.</p>

</div>

<div class='content chap10-para-head'><strong>Rationale</strong></div>
<div class='content chap10-para'>
<p>Collection of these clinically important brain cancer subtypes has been recommended by CBTRUS.</p>

</div>


<div class='content chap10-para'>
<p><strong>Definition</strong></p>
<p>If a mutation or alteration is in the name of the histopathology, it is required for diagnosis as it helps distinguish among clinically important subtypes within ICD-O-3. </p>
<ul>
<li><em>IDH mutation status</em> distinguishes between clinically important subtypes within ICD-O-3 9400/3, Diffuse astrocytoma and 9401/3, Anaplastic astrocytoma.</li>
<li><em>IDH mutant and 1p/19q co-deletion</em> distinguishes between clinically important subtypes within ICD-O-3 code 9450/3, Oligodendroglioma and 9451/3, Anaplastic Oligodendroglioma.</li>
<li><em>IDH-wildtype</em> distinguishes clinically important subtypes within ICD-O-3 9400/3, Diffuse astrocytoma, 9401/3, Anaplastic astrocytoma and 9440/3, Glioblastoma, Epithelioid glioblastoma and Glioblastoma, NOS (note that the new ICD-O-3 code 9445/3 applies to Glioblastoma, IDH-mutant; information regarding this subtype is not collected using this data item).</li>
<li><em>SHH-activation and TP53-wildtype</em> distinguishes between clinically important subtypes within ICD-O-3 histology code 9471/3, Medulloblastoma.</li>
<li><em>C19MC alteration</em> status distinguishes a clinically important highly aggressive subtype within ICD-O-3 9478/3, Embryonal tumor with multilayered rosettes.</li>
<li><em>Pediatric-type diffuse low-grade gliomas</em>: 9385/3 Diffuse hemispheric glioma, H3-G34-mutant, Diffuse midline glioma, H3 K27-altered, Diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype, and Infant-type hemispheric glioma.</li>
<li><em>Ependymal tumors</em> are distinguished by mutations required for diagnosis among clinically important subtypes: 9396/3 Posterior fossa group A (PFA) ependymoma, Posterior fossa group B (PFB) ependymoma, Spinal ependymoma, _MYCN_-amplified, Supratentorial ependymoma, <em>YAPI</em> fusion-positive, and Supratentorial ependymoma, <em>ZFTA</em> fusion-positive.</li>
<li><em>Pediatric-type diffuse low-grade gliomas</em> are distinguished among subtypes by mutations required for diagnosis: 9421/1 Diffuse astrocytoma, _MYB_-or _MYBL1_-altered, Diffuse low-grade glioma, MAPK pathway-altered, and Pilocytic astrocytoma.</li>
<li><em>Circumscribed astrocytic tumors</em> are distinguished among subtypes by mutations required for diagnosis: 9430/3 Astroblastoma, MN1-altered and Astroblastoma.</li>
<li><em>Other CNS embryonal tumors</em> are distinguished among subtypes by mutations required for diagnosis: 9500/3 CNS neuroblastoma_, FOXR2_-activated, CNS tumor with <em>BCOR</em> internal tandem duplication, and Neuroblastoma, NOS.</li>
</ul>

</div>

<div class='content chap10-para'><strong>Codes</strong></div>
<table>
        <tr class='code-row'><td class='code-nbr'>01</td><td class='code-desc'>Astrocytoma, IDH-mutant, grade 2 (9400/3)</td></tr>
        <tr class='code-row'><td class='code-nbr'>02</td><td class='code-desc'>Diffuse astrocytoma, IDH-wildtype (9400/3)</td></tr>
        <tr class='code-row'><td class='code-nbr'>03</td><td class='code-desc'>Astrocytoma, IDH-mutant, grade 3 (9401/3)</td></tr>
        <tr class='code-row'><td class='code-nbr'>04</td><td class='code-desc'>Anaplastic astrocytoma, IDH-wildtype (9401/3)</td></tr>
        <tr class='code-row'><td class='code-nbr'>05</td><td class='code-desc'>Glioblastoma, IDH-wildtype (9440/3)</td></tr>
        <tr class='code-row'><td class='code-nbr'>06</td><td class='code-desc'>Oligodendroglioma, IDH-mutant and 1 p/19q co-deleted (9450/3)</td></tr>
        <tr class='code-row'><td class='code-nbr'>07</td><td class='code-desc'>Oligodendroglioma, IDH-mutant and 1p/19q co-deleted, grade 3  (9451/3)</td></tr>
        <tr class='code-row'><td class='code-nbr'>08</td><td class='code-desc'>Medulloblastoma, SHH-activated and TP53-wildtype (9471/3)</td></tr>
        <tr class='code-row'><td class='code-nbr'>09</td><td class='code-desc'>Embryonal tumor with multilayered rosettes, C19MC-altered (9478/3)</td></tr>
        <tr class='code-row'><td class='code-nbr'>10</td><td class='code-desc'>Diffuse hemispheric glioma, H3-G34 mutant (9385/3)</td></tr>
        <tr class='code-row'><td class='code-nbr'>11</td><td class='code-desc'>Diffuse midline glioma, H3 K27-altered (9385/3)</td></tr>
        <tr class='code-row'><td class='code-nbr'>12</td><td class='code-desc'>Diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype (9385/3)</td></tr>
        <tr class='code-row'><td class='code-nbr'>13</td><td class='code-desc'>Infant-type hemispheric glioma (9385/3)</td></tr>
        <tr class='code-row'><td class='code-nbr'>14</td><td class='code-desc'>Posterior fossa group A (PFA) ependymoma (9396/3)</td></tr>
        <tr class='code-row'><td class='code-nbr'>15</td><td class='code-desc'>Posterior fossa group B (PFB) ependymoma (9396/3)</td></tr>
        <tr class='code-row'><td class='code-nbr'>16</td><td class='code-desc'>Spinal ependymoma, MYCN-amplified (9396/3)</td></tr>
        <tr class='code-row'><td class='code-nbr'>17</td><td class='code-desc'>Supratentorial ependymoma, YAP1 fusion-positive (9396/3)</td></tr>
        <tr class='code-row'><td class='code-nbr'>18</td><td class='code-desc'>Supratentorial ependymoma, ZFTA fusion-positive (9396/3)</td></tr>
        <tr class='code-row'><td class='code-nbr'>19</td><td class='code-desc'>Diffuse astrocytoma, MYB- or MYBL1-altered (9421/1)</td></tr>
        <tr class='code-row'><td class='code-nbr'>20</td><td class='code-desc'>Diffuse low-grade glioma, MAPK pathway-altered (9421/1)</td></tr>
        <tr class='code-row'><td class='code-nbr'>21</td><td class='code-desc'>Astroblastoma, MN1-altered (9430/3)</td></tr>
        <tr class='code-row'><td class='code-nbr'>22</td><td class='code-desc'>CNS neuroblastoma, FOXR2-activated (9500/3)</td></tr>
        <tr class='code-row'><td class='code-nbr'>23</td><td class='code-desc'>CNS tumor with _BCOR_ internal tandem duplication (9500/3)</td></tr>
        <tr class='code-row'><td class='code-nbr'>85</td><td class='code-desc'>Not applicable: Histology not 9385/3, 9396/3, 9400/3, 9401/3, 9430/3, 9440/3, 9450/3, 9451/3, 9471/3, 9478/3, 9421/1, 9430/3, 9500/3</td></tr>
        <tr class='code-row'><td class='code-nbr'>86</td><td class='code-desc'>Benign or borderline tumor 

Excludes: 9421/1 (codes 19-20)</td></tr>
        <tr class='code-row'><td class='code-nbr'>87</td><td class='code-desc'>Test ordered, results not in chart</td></tr>
        <tr class='code-row'><td class='code-nbr'>88</td><td class='code-desc'>Not applicable: Information not collected for this case  
(If this item is required by your standard setter, use of code 88 will result in an edit error.)</td></tr>
        <tr class='code-row'><td class='code-nbr'>99</td><td class='code-desc'>Not documented in patient record  
No microscopic confirmation  
Brain molecular markers not assessed or unknown if assessed</td></tr>
</table>

<div class='content chap10-para'>
<p>Each Site-Specific Data Item (SSDI) applies only to selected primary sites, histologies, and years of diagnosis. Depending on applicability and standard-setter requirements, SSDIs may be left blank.</p>

</div>
